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Patients receiving cadaveric kidney transplants often
experience delayed graft function. As iodinated contrast
media injection (ICMI), necessary for cerebral angiography,
which is often used to diagnose brain death, can be
nephrotoxic, we compared renal function recovery (RFR) and
1-year and long-term graft survival according to the method
used to diagnose brain death. Data from 9921 cadaveric
kidneys, transplanted between 1 January 1998 and 31
December 2003, were retrieved from the French National
Registry for organ donation. We defined RFR as the number
of days for the recipient to reach a plasma creatinine less
than 250 lmol/l, and/or a 24-h urine output greater than
1000 ml. RFR and 1-year and long-term graft survival were
compared between four different donor groups (according to
ICMI and diabetes mellitus). A total of 41.5% of deceased
donors received ICMI before organ procurement and 1.95%
of them were diabetic. History of ICMI or diabetes in the
donor did not influence RFR or 1-year graft survival.
Long-term graft survival was decreased in the group of
patients transplanted with a diabetic graft as compared to
patients transplanted with a non-diabetic graft (P¼ 0.001).
History of ICMI in the donor did not affect long-term graft
survival in the non-diabetic donor group (P¼ 0.2); however,
in the diabetic group, ICMI tended to decrease long-term
graft survival (P¼ 0.056). ICMI did not affect RFR or graft
survival in non-diabetic deceased donors. However, its use
in diabetic deceased donors requires further study.
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Because of organ shortage, the criteria for deceased kidney
donors have been broadened. The risk of this change is that
the donor pool now includes donors with hypertension,
advanced age, or diabetes mellitus, which influence initial
graft function and long-term graft survival.1–16
In France, the use of cerebral angiography to diagnose
brain death has become one of the accepted techniques,
showing the irreversible arrest of cerebral circulation.17–20
Compared to the recording of two successive flat electro-
encephalographies separated by 4 h, angiography decreases
the time between brain death diagnosis and organ removal.
Furthermore, its interpretation is not influenced by central
nervous system depressant drugs or hypothermia (up to
281C) and it is available 24/7 in almost all French hospitals
designed to perform organ procurement contrary to the
electroencephalographies. However, the use of iodinated
contrast media injection (ICMI) for angiography can cause
contrast-induced nephropathy (CIN) especially in patients
with previously compromised renal function, for example
after severe hypotension or after cardiovascular surgery.21–24
As for all ICMI exams in intensive care unit, adequate
hydratation is used to prevent CIN; however, mannitol,
bicarbonates, or diuretic injections are not usually used in
France. Diabetic patients are particularly prone to iodinated
CIN sometimes requiring the use of renal replacement
therapy, temporarily or permanently.21 CIN is due to
vasoconstriction-mediated renal medullary ischemia and
direct toxic damage to the renal tubular epithelial cells.22–25
In addition, in the setting of kidney transplantation, cold
ischemia induces an ischemia/reperfusion stress that is
responsible for tubular damage, which may decrease graft
survival.16 Some experimental studies have suggested that
this ischemic effect can be worsened by ICMI.23–24 However,
several clinical observations suggest that ICMI does not
influence graft survival, even in diabetic donors; however,
these studies are based on small numbers of patients and
require further investigation.26,27
In order to elucidate whether ICMI and/or diabetic status
of the donor affects renal function recovery (RFR) and/or
kidney graft survival, we conducted a retrospective analysis of
the prospective French National Registry of organ donation.
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RESULTS
Between 1 January 1998 and 31 December 2003, there were a
total of 12 050 kidney transplantations in France. Five
hundred and seventy-nine grafts were excluded from the
study because they were from living donors and 1366
cadaveric grafts were excluded because ICMI status was not
documented in the database. We were able to analyze RFR
only for 6023 cadaveric grafts, because for the other grafts,
one or both of the early renal function criteria were not
correctly fulfilled in the database. Out of them, 44.2%
(n¼ 2663) received ICMI and 1.7% (n¼ 74) were from
diabetic donors. However, graft-survival data were comple-
tely fulfilled in the database for 9921 grafts, allowing for all of
them the analysis of 1-year and long-term survival. Out of
them, 41.5% (n¼ 4123) received ICMI, and 1.95% (n¼ 143)
were from diabetic donors.
Within the diabetic and non-diabetic subgroups, there
were no significant differences between donors who received
ICMI and those who did not (Table 1). However, comparison
between the subgroups revealed that donor age (P¼ 0.0001),
death due to vascular causes (P¼ 0.0001), recipient age
(P¼ 0.0023), and cold ischemia time (P¼ 0.0007) were
significantly higher in the diabetic donor population
(Table 1).
Renal function recovery
Both renal function criteria (number of days for the recipient
to reach a plasma creatinine less than 250 mol/l or number of
days for the recipient to reach a 24-h urine output greater
than 1000 ml) were separately analyzed. Neither ICMI nor
history of diabetes in the donor significantly influenced RFR
regardless of the criteria used (Table 2). However, as
previously shown, the number of days for the recipient to
reach a 24-h urine output greater than 1000 ml was
significantly linked to donor hypotension, donor plasma
creatinine, time on waiting list, previous transplantation, and
panel reactive antibody. The number of days for the recipient
to reach a plasma creatinine less than 250 mmol/l was
significantly associated to the same five factors plus seven
other previously described factors (Table 2).
Graft survival
The mean follow-up time after renal transplantation was
50.9716.4 months. Overall 1-year graft survival was 91.1%
(95% confidence interval (CI) 90.4–91.7%) and 4-year graft
survival was 82.5% (81.6–83.4%).
One-year survival was not statistically different between
the four groups (P¼ 0.1); however, long-term graft sur-
vival was significantly reduced in diabetic donor grafts
as compared to non-diabetic donor grafts (P¼ 0.00001)
(Figure 1).
In the non-diabetic donor graft subgroup, there were no
differences between survival according to ICMI after 1 year
(DIþ 91.7% (90.7–92.7%) vs DI 90.7% (89.8–91.6)) or
after 4 years (DIþ 83.6% (82.2–85%) vs DI 87.3%
(81–83.5%)) (P¼ 0.2).
In contrast, in the subgroup of diabetic donor grafts,
ICMI did not influence 1-year survival (1-year survival
Dþ Iþ 83.3% (95% CI 74.3–92.3%) vs Dþ I 89.64%
(82.8–96.4%)) but significantly decreased 4-year survival
(Dþ Iþ 57.9% (44.9–71.0%) vs Dþ I 75.7% (64.9–
86.6%)) (P¼ 0.001).
Risk factors analysis
The result of univariate analysis demonstrated that 1- and 4-
year graft survival were significantly influenced by the
following: donor age over 55 years, cerebrovascular cause of
death, diabetic status of the donor, cold ischemia time
424 h, recipient age 460 years, time spent on waiting list,
panel reactive antibody 415%, female donor to male
recipient, previous kidney transplantation, and human
leukocyte antigen mismatch.
Using multivariate analysis, adjusting these previous
factors for diabetes and ICMI (Table 3), significant factors
worsening long-term graft survival were vascular cause of
cerebral death (relative risk¼ 1.3, P¼ 0.0001), donor age
455 years (relative risk¼ 1.32, P¼ 0.0001), and recipient age
460 years (relative risk¼ 1.37, P¼ 0.0001). Neither diabetes
nor ICMI reached significance for 1- or 4-year graft survival.
However, their interaction trended towards a worse prognosis
of 4-year survival (relative risk of 1.8, P¼ 0.056).
Table 1 | Characteristics of donors and recipients according to ICMI status and diabetes mellitus status
ICMI+ ICMI
I+D+ I+D ID+ ID P-value
Donor sex M/W (%) 58/42 64/36 65/35 65/35 0.61
Donor age 0–15/16–54/+55 (%) 0/56/44 5/78/17 0/61/39 5/77/18 o0.0001
Vascular cause of death (yes/no) 65/35 42/58 62/38 46/54 o0.0001
Sex ratio recipient M/W (%) 62/38 64/36 58/42 63/37 0.59
Recipient age 0–15/16–29/39–59/+60 (%) 0/1/73/26 4/12/70/14 0/3/69/28 4/13/68/15 o0.0001
Mean waiting time (months)7s.d. 14.4719.9 17.9721.5 18.7720.5 17.8721.7 0.69
Previous transplantation (yes/no) 11/89 14/86 13/87 13/87 0.34
PRA 0–14/15–69/470% (%) 86/12/2 84/10/6 88/4/8 86/8/6 0.09
Mean cold ischemia time 0–23/+24 (%) 49/51 68/32 61/39 69/31 0.003
Mismatch 0/41 (%) 2/98 3/97 5/95 3/97 0.39
ICMI, iodinated contrast media injection; M/W, male/women ratio; PRA, panel reactive antibody activity; s.d., standard deviation.
I+D+, diabetic organ donors who received ICMI; I+D, non-diabetic organ donors who received ICMI; I D+, diabetic organ donors who did not receive ICMI; I D,
non-diabetic organ donors who did not receive ICMI; mismatch, number of HLA-A, B, and DR mismatching (0–6).
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DISCUSSION
Using data from a national registry, we have found that ICMI
does not adversely affect RFR, and short or long-term renal
graft survival in non-diabetic organ donors. However,
diabetic organ donors who received ICMI exhibited a trend
towards impaired long-term graft survival, suggesting that
further studies are needed for diabetic donors.
Because of organ shortage, marginal renal donors are
increasingly been used for transplantation, resulting in the
use of kidneys from donors with a history of hypertension or
diabetes.1 Diabetic donor kidneys now represent 2.3% of all
deceased renal donors in the US,1 and 1.9% in France.
Therefore, adequate management of these suboptimal donors
is critical.15,16,28–32 Time is of the essence in brain death
donors because of myocardial dysfunction, vasoplegia, and
diabetes insipides, all of which lead to highly unstable
hemodynamics and impart a high risk for acute renal failure
Table 2 | Delayed graft function analysis: slopes (b) and P-values
Time until recipient plasma creatinine p250 lmol/l Time until recipient 24-h urine output X1000 ml
b P-value b P-value
Donor characteristics
Sex 0.2 0.8 0.02 0.9
Age (mean) 0.11 0.0001 0.006 0.7
Vascular cause of death 1.5 0.04 0.4 0.5
Donor cardiac arrest 1.9 0.03 1.01 0.13
Donor hypotension 3.8 0.0001 2.1 0.001
Diabetes mellitus 3.8 0.2 0.8 0.7
ICMI 0.8 0.2 0.15 0.8
Last donor plasma creatinine (mmol/l) 0.05 0.0001 0.02 0.0002
Oligoanuria before extraction 3.4 0.04 1.8 0.09
Recipient characteristics
Sex (F) 1.7 0.01 0.5 0.3
Age (mean) 0.1 0.0001 0.02 0.2
Waiting time (months) 0.05 0.001 0.03 0.02
Previous transplantation 2.6 0.01 2.1 0.009
Peak PRA level
15–69% 2.2 0.07 1.53 0.09
X70% 1.4 0.3 0.64 0.6
Others
Female graft to male recipient 0.03 0.9 0.8 0.2
Cold ischemia length X24 h 3.2 0.001 1.09 0.055
HLA ABDR mismatch 0.86 0.68 0.5 0.8
Kidney–pancreas transplantation 5.8 0.09 1.6 0.53
F, female; HLA, human leukocyte antigen; ICMI, iodinated contrast media injection; PRA, panel reactive antibody activity.
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Figure 1 | Actuarial survival curves according to diabetes and
ICMI. IþDþ : diabetic organ donors who received ICMI; IDþ :
diabetic organ donors who did not receive ICMI; IþD: non-diabetic
organ donors who received ICMI; ID: non-diabetic organ donors
who did not receive ICMI.
Table 3 | Effect of diabetes and ICMI on graft survival
adjusted on other risk factors associated with graft survival
One-year survival Overall survival
OR P-value HR P-value
Diabetes mellitus 0.97 0.94 1.17 0.5
Contrast media injection 0.91 0.26 0.95 0.33
Diabetes mellitus and contrast
media injection interaction
1.85 0.22 1.8 0.056
Vascular cause of death 1.4 0.0001 1.3 0.0001
Donor age (years)
0–16 1.8 0.006 1.3 0.11
16–54 1 1
55+ 1.11 0.3 1.32 0.0001
Cold ischemia time
p24 h 1 1 1
424 h 1.15 0.11 1.01 0.8
Recipient age (years)
0–16 0.78 0.37 0.99 0.95
16–29 1 1
30–59 0.96 0.76 1.18 0.046
60+ 1.44 0.02 1.37 0.0001
HR, hazard ratio; ICMI, iodinated contrast media injection; OR, odds ratio.
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and cardiac arrest before organ removal.15,16 Although acute
tubular necrosis, a process that is often sustained during the
procurement and storing of the graft, is reversible, it often
leads to delayed graft function and decreases long-term graft
survival.16,33–35 In France, after an initial flat electroence-
phalography, brain death diagnosis must be confirmed by a
second flat electroencephalography, 4 h later, a delay that
increases the risk of donor hemodynamic worsening. The use
of angiography reduces the time before procurement and
decreases this risk. However, physicians are often reluctant to
use ICMI in patients who are hemodynamically unstable and/
or who have history of diabetes. The nephrotoxicity of
contrast media has been documented in patients with
previously compromised renal function (chronic renal fail-
ure, diabetes mellitus, hypovolemia, or prolonged hemo-
dynamic shock).21 Therefore, it is surprising that, in our
study, RFR was not worsened by ICMI in organ donor
population even in the diabetic population.
The main point of this study was to examine a modifiable
and controversial potential risk factor. Many other surveys
have looked at non-modifiable risk factors, implicating
several donor or recipient characteristics. For example, the
use of diabetic donors is significantly associated with a poor
long-term graft survival in many studies.1,7 Other factors that
have previously been demonstrated to significantly influence
1-year and long-term graft survival include donor and
recipient ages, cold ischemia time, and vascular cause of
death.2–4,6,8–14,16 In agreement with these previous studies,
our results confirmed the influence of these risk factors.
Except for cold ischemia time and human leukocyte antigen
mismatch, these risk factors cannot be modified; however,
ICMI and organ donor management can and should be
controlled.
More precised data about contrast injection were un-
fortunately not available due to the design of the study. The
exact method of angiography for brain death diagnosis
(global or selective injection of cerebral vessels) is not
routinely collected in the CRISTAL database, and neither are
the product or the dose used. However, current procedures
aim to use the least quantity of contrast media, usually less
than 50 ml of a non-ionic contrast media. Recently, injected
cerebral computed tomography has also been implemented
as a cerebral angiography, according to the prospective study
of Dupas.19 This method requires injection of 120 ml of
iohexol, twice the dose used in conventional arteriography.
However, the crossover between both periods (the current
study and CT scan implementation) is very narrow.
Furthermore, owing to the large number of patients included
in the current study, occasional deviation to the 50 ml of
contrast media injection should not have significantly
affected the results described herein.
This current study is a retrospective analysis of a
prospective registry, which includes a large number of
patients. Even if the criteria used by the French database
are probably not the best ones to access RRF, our study
suggests that ICMI in a non-diabetic donor will not alter
early renal function after transplantation or long-term graft
survival. Although neither diabetes nor ICMI were risk
factors for RFR, long-term survival was shorter in the entire
group of diabetic donors and even worse for the patients who
were transplanted with a diabetic graft from a donor who
received ICMI. However, after adjustment for general risk
factors, including cold ischemia time, this association was no
longer significant, although a positive trend remained
(P¼ 0.056). The small number of diabetic donors and the
retrospective status of this analysis do not allow us to
definitively determine whether or not ICMI is a contra-
indication for diabetic donors. Therefore, the use of ICMI in
diabetic donors needs further investigations. Ideally, a
prospective randomized study of diabetic donors is required
to determine the effect of the ICMI on graft survival.
Preservation of hemodynamic status using plasma expan-
sion and vasoactive drugs is still of great importance in
preventing CIN and delayed graft function.16 In fact,
adequate prevention of CIN provided by ICU physicians
almost certainly played a role in the overall good prognosis
of this cohort. The use of free radical scavengers, such as
N-acetylcysteine, has been shown to be nephroprotective
and their administration before ICMI, in addition to other
measures, could be useful during the management of brain
death donors.16,36–40 Moreover, utilization of the lower doses
of contrast media has to be respected. Development of
alternative techniques as CO2 angiography can be good
alternatives avoiding entirely the risk of CIN or allergic
reaction, but are so far not evaluated and not yet legally
admitted as brain death diagnosis in France.
In summary, the increased use of suboptimal organ
donors requires better and faster management in order to
optimize graft survival. Despite the risk of CIN, cerebral
angiography reduces the delay to transplant procurement by
rapidly confirming brain death. This study shows that ICMI
can safely be used for angiography without harming initial
RFR and grafts survival in non-diabetic donors. However, in
diabetic donors, brain death should be confirmed by other
means than cerebral angiography if the hemodynamic status
of the donor allows it, because, in addition to all the potential
risk factors of these specific donors, the ICMI has a
supplemental potential risk for decreased long-term graft
survival.
MATERIALS AND METHODS
The database (CRISTAL) of the French transplantation agency ‘Agence
de Biome´decine’ (previously named ‘Etablissement franc¸ais des
Greffes’) was used for this study. This database prospectively collects
the information of all donors and recipients of all transplantations in
France. All recipients of cadaveric kidney grafts, transplanted between
1 January 1998 and 31 December 2003, were reviewed. Living donors,
donors in whom the method of brain death diagnosis was not
available in CRISTAL, and recipients whose follow-up was not
completed (i.e. no data for more than 1 year) were excluded.
In France, cerebral angiography in order to assess brain death is
routinely performed via the arterial route. Cerebral vessels can be
opacified either from the aortic arch (global injection) or specifically
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via each carotid and posterior cerebral artery (selective injection).
Any of these procedures usually uses less than 50 ml of a non-ionic
contrast media agent such as iohexol.
The following donor characteristics were analyzed: sex, age,
cerebrovascular cause of death, history of diabetes mellitus, brain
death diagnostic method. Recipient characteristics were also analyzed
and included the following: sex, age, time on waiting list before
transplantation, previous transplantation(s), peak panel reactive
antibody level, human leukocyte antigen mismatch (0–6), female
donor to male recipient, cold ischemia time, graft and patient survival.
We compared four groups: donors exposed to ICMI and diabetic
(IþDþ ), donors exposed to ICMI and non-diabetic (IþD),
donors not exposed to ICMI and diabetic (IDþ ), and donors not
exposed to ICMI and non-diabetic (ID).
RFR was defined as in the database by the number of days for the
recipient to reach a plasma creatinine less than 250 mmol/l or the
number of days for the recipient to reach a 24-h urine output greater
than 1000 ml. ‘Delayed graft dysfunction’ is not a criteria available
by itself in the French database and could only be estimated by these
two early renal function indicators.
Graft survival was defined as the patient being alive and not on
renal replacement therapy.
Statistics
All statistical analyses were performed using the SAS software
package version 8.1 (SAS Institute Inc., Cary, NC, USA).
Generalized linear models were used to examine factors
associated with an early delayed graft function. Results are
expressed with slopes (b) and P-values. The Kaplan–Meier
survival method was used to determine graft survival and the
log-rank test used for comparisons. Significant increase of
graft loss associated with diabetes and contrast media and
their interaction were investigated using a logistic regression
model for 1-year survival and the Cox proportional hazards
regression model for overall survival. A two-sided P-value of
0.05 was considered statistically significant.
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